Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
Wang Qu(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiping Zhou(National Cancer Center), Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaobing Chen(Stomatology Hospital), Aimin Zang(Affiliated Hospital of Hebei University), Xiujuan Qu(First Hospital of China Medical University), Yunbo Zhao(University of Science and Technology of China), Bo Liu(Hubei University of Arts and Science), Liangjun Zhu, Hao Yan(Zhejiang Center for Disease Control and Prevention), Shengmian Li(Hebei Medical University), Zimin Liu(Qingdao University)
Cited by 10
Related Papers
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
|Journal of Hematology & Oncology|2021|149
The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
|Biological Trace Element Research|1997|122